Aptar Pharma Announces Agreement with Pulmotree to Develop and Promote Kolibri™ Non-Propellant Liquid Inhaler Platform
Aptar Pharma announced that it has entered into an exclusive collaboration agreement with PULMOTREE to lead the development and promotion of their Kolibri™ Non-Propellant Liquid Inhaler (NPLI) platform. As part of the agreement, Aptar Pharma will provide PULMOTREE with their full support to accelerate growth, be the main point of contact for customers, and have the ability to complement the Kolibri™ NPLI Platform Technology with Aptar’s suite of comprehensive services. Non-Propellant Liquid Inhalers encompass nebulizers and soft-mist inhalers, and are being developed as an alternative to propellant-based systems. PULMOTREE’s Kolibri™ utilizes a robust breath-triggered Vibrating Mesh aerosolization engine with unique breath-guidance capabilities to enhance targeted lung deposition. The Kolibri™ technology is award-winning and incorporates advanced connectivity features.